Effectiveness of Endoscopic Papillectomy With Stent for Treating Duodenal Papillary Adenoma

Beijing Friendship Hospital79 enrolled

Overview

This is a retrospective study, including 79 patients with duodenal papillary adenoma, who treated with Endoscopic Papillectomy (EP) at Beijing friendship hospital. The cohort included patients who underwent EP with or without Pancreatic Duct (PD) and Common Bile Duct (CBD) stent placement. The investigators assessed the outcomes of EP and the impact of stent placement on complications and recurrence rates.

Duodenal papillary adenoma, a potentially malignant benign tumor is primarily treated with endoscopic papillectomy. Despite its efficacy, endoscopic papillectomy has a high complication rate. This study investigates whether pancreatic duct and common bile duct stent placement can mitigate these complications. In a retrospective analysis, 79 patients with duodenal papillary adenoma, treated with endoscopic papillectomy at our center, were studied. The cohort included patients who underwent endoscopic papillectomy with no stents placement, common bile duct stent placement alone, pancreatic duct stent placement alone, or stents placement in both ducts. Complete resection rates did not significantly differ between patients with or without stent placement. Early complication rates were similar across groups. However, significant reduction in common bile duct stenosis was observed in the stenting group. Furthermore, stent placement correlated with lower adenoma recurrence rates during follow-up. Thus, Pancreatic duct and common bile duct stent placement in endoscopic papillectomy may decrease late complications, particularly common bile duct stenosis, and reduce the recurrence of duodenal papillary adenoma.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Duodenal Adenoma Complication of Treatment

Interventions

Stent Placement in Pancreatic and Bile DuctsPROCEDURE

Post-resection, endoscopic retrograde cholangiopancreatography (ERCP) was performed for stent placement in pancreatic or bile ducts as needed, with X-ray confirmation of stent positioning.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥18 years. * Identification of duodenal papillary lesions via gastroscopy or duodenoscopy. * Intraductal involvement \<20mm. * Absence of preoperative peripheral lymph node metastasis and pancreatic/biliary duct stenosis (verified by CT, MRI, or other imaging). * Postoperative biopsy confirming adenoma. Exclusion Criteria: * Diagnosis of familial adenomatous polyposis or multiple hamartoma syndrome. * Patients undergoing pancreaticoduodenectomy within a month post-EP for residual lesions.

Locations (1)

Beijing Friendship Hospital

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Rate of complications

Complications related with Endoscopic Papillectomy (EP), including pancreatitis, cholangitis, bleeding, perforation, hyperamylasemia, stenosis. The results of intraoperative endoscopic observation, postoperative symptoms and signs, blood routine examination, amylase, lipase, and imaging and endoscopic examination during follow-up were measured.

Time frame: through study completion, an average of 1 year

Rate of complete resection

The pathological margins results were used to determine whether the lesion was completely resected.

Time frame: 1 week after the operation

Secondary Outcomes

Rate of recurrence

Endoscopic observation and biopsy results were used to find recurrence.

Time frame: Within 3 years after the operation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.